Press Releases

MEXICO CITY--(BUSINESS WIRE)-- AM Best has revised the outlook to positive from stable for the Long-Term Issuer Credit Rating (Long-Term ICR) and affirmed the Financial Strength Rating (FSR) of A+ (Superior), the Long-Term ICR of “aa-” (Superior) and the Mexico National Scale Rating (NSR) of “aaa.MX” (Exceptional) of Berkley International Fianzas Mexico S.A. (BFM) (Mexico City, Mexico). The outlook of the FSR and NSR is stable.

BFM is a member of W. R.... (continue reading...)

Not for distribution to United States newswire services or for dissemination in the United States.

VANCOUVER, BC / ACCESSWIRE / June 6, 2024 / Arras Minerals Corp. (TSXV:ARK) ("Arras" or the "Company") is pleased to announce that further to its news release dated May 29, 2024, it has closed its previously announced non-brokered private placement (the "Offering") for an aggregate of 20,268,662 units of the Company ("Units") at a price per Unit of C$0.26 for aggregate... (continue reading...)

LA VISTA, Neb.--(BUSINESS WIRE)-- IPA Capital Markets, a division of Marcus & Millichap (NYSE: MMI), specializing in capital markets services for major private and institutional clients, announced the $72.24 million refinance of La Vista City Centre, a growing master-planned multifamily, office and retail development in La Vista, Nebraska.

Frank Montalto, IPA Capital Markets managing director based in the firm’s Chicago office, secured the financing on behalf of... (continue reading...)

VANCOUVER, BC / ACCESSWIRE / June 6, 2024 / Apex Critical Metals Corp. (CSE:APXC)(OTCQB:APXCF) ("Apex" or the "Company"), is pleased to announce that the Company has entered into an Earn-In Option Agreement ("the Agreement") with Discovery Lithium inc. ("Discovery Lithium") and DG Resource Management LTD. ("DG Resource") on the West James Bay property portfolio. The portfolio includes the Mantle, Cirrus East, Cirrus West, Neptune, Alto, Opus and Bruce Lake projects... (continue reading...)

WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes (“CD8+ CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders with the aim of addressing the significant unmet... (continue reading...)